Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma
| Autor: | Devansu Tewari, B. Saffari, Bradley J. Monk, Robert A. Burger, N. Arora, Chad A. Cowan |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
medicine.medical_specialty Bevacizumab Angiogenesis Fallopian tube carcinoma Angiogenesis Inhibitors Antineoplastic Agents Antibodies Monoclonal Humanized chemistry.chemical_compound Fallopian Tube Neoplasm Internal medicine Ovarian carcinoma medicine Fallopian Tube Neoplasms Humans business.industry Obstetrics and Gynecology Antibodies Monoclonal Middle Aged medicine.disease female genital diseases and pregnancy complications Vascular endothelial growth factor chemistry Fallopian tube cancer Female business Ovarian cancer medicine.drug |
| Zdroj: | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 18(2) |
| ISSN: | 1525-1438 |
| Popis: | The targeting of angiogenesis pathways in the treatment of gynecological cancers is an exciting development in cancer therapy. Bevacizumab has been shown to have activity in ovarian cancer through its inhibition of the vascular endothelial growth factor. Fallopian tube carcinoma is a rare malignancy and is often treated in a similar manner as ovarian carcinoma. We present a case of a complete response in a woman with refractory metastatic fallopian tube carcinoma treated with bevacizumab. This report demonstrates the significance of anti-angiogenesis therapy in the treatment of these tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text